Our employees are focused on putting science, technology and innovation to work to make a difference in patients' lives. This effort starts in the labs, moves into the clinic and continues with our commitment to ensuring patients can access the therapies they need.


Regeneron offers comprehensive patient programs, such as DUPIXENT My Way, MyPraluent and EYLEA4U, to help eligible patients throughout their treatment journey with insurance eligibility support, patient resources, financial assistance and access to free medicine.

These comprehensive patient programs provide support for patients throughout their treatment journey by offering insurance eligibility support, financial assistance and free medicine to eligible patients.

For patients covered through government healthcare programs such as Medicare who may need assistance with out-of-pocket costs, an independent co-pay assistance foundation may be able to help. Specialists can help patients understand foundation options and provide referrals. Additional services include access to educational information and clinical support for physicians, nurses and pharmacists.

Regeneron does not influence or control the operations of independent co-pay assistance foundations and cannot guarantee assistance will be provided.


We are committed to bringing important new medicines to people with serious diseases.

Before a new treatment is widely available to the public, it undergoes years of rigorous clinical testing to satisfy the safety and efficacy criteria required for regulatory approval. Approval by a country or region's health regulatory authority, such as the U.S. Food and Drug Administration, allows the appropriate group of people to access a medicine.

In some cases, a potentially beneficial therapy may not yet be approved by regulatory authorities. Therefore, Regeneron has established a Compassionate Use Policy to help provide access to an investigational medical product, with the required permission from a health regulatory authority.


In the USA, this type of compassionate use program is also known as an Expanded Access Program (EAP) and is intended for patients with serious or life-threatening conditions who do not have any viable or available treatment options, and are unable to participate in ongoing clinical trials. To view a list of Regeneron’s open clinical trials, visit clinicaltrials.gov.

To ensure the safety of patients, we have developed certain criteria to evaluate Compassionate Use requests. All such requests are required to be in accordance with local laws and regulations, as well as with Regeneron Policies. While Regeneron is committed to reviewing each request carefully, fairly and on a case-by-case basis, we cannot guarantee access to any specific investigational medical product by any individual patient.

Requests for compassionate use must be initiated by a treating physician, so if you are a patient or caregiver, please ask your doctor for support in this process. Physicians should send compassionate use requests to CompassionateUse_Request@regeneron.com. Regeneron will acknowledge receipt of a physician’s request within five business days.

The following criteria must be met for consideration of Compassionate Use request:

  1. There is sufficient data to expect that the investigational medical product will have a favorable benefit-risk profile.
  2. The regulatory agency in the country where the patient resides must also approve the proposed use of the investigational drug, when required.
  3. Providing the investigational medical product will not interfere with or compromise its clinical development. This means that adequate supply of the investigational medical product must be available to perform necessary clinical studies before access is provided through the Compassionate Use program.
  4. There is a legitimate medical need documented and submitted by the treating physician.
  5. The physician initiating the Compassionate Use request and providing treatment must be qualified in terms of background, education, and experience to carry out the proposed protocol.
  6. The initiating physician agrees to assume all responsibilities and obligations to comply with the relevant regulatory requirements.



Our company was built on the fundamental goal of helping patients, and we regularly engage with advocacy organizations to help empower patients.

One example is the Arthritis Foundation, a leading organization that provides life-changing information and resources, access to optimal care, advancements in science and community connections. Together, we created patient advocacy summits and patient ambassador programs with the goal of catalyzing national and local advocacy efforts.

We also aim to support community needs through unique programs and active engagement with the advocacy organizations that represent the patients we serve.

Regeneron is a national Eye-Care Services Sponsor for ITNAmerica/Rides in Sight. ITNAmerica is the first, national nonprofit transportation network committed to providing safe, low-cost, community-based transportation options for seniors and those with vision loss.

By expanding mobility options for people who may have difficulty securing transportation, and by developing Rides in Sight, the largest national transportation database and hotline for seniors and those with vision loss, ITNAmerica has helped many throughout the United States to remain independent and empowered.


Learn more